Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danny Vesprini

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Cancer|April 16, 2013
Reply to Monitoring of seminoma patients with serum markersDanny Vesprini, Padraig Warde, Peter Chung
Current Opinion in Urology|March 2, 2013
Predicting high risk disease using serum and DNA biomarkersDanny Vesprini, Stanley Liu, Robert Nam
International Journal of Radiation Oncology, Biology, Physics|September 22, 2023
Elective Nodal Irradiation: Old Game, New SPORTDanny Vesprini, Angela Pathmanathan, Vedang Murthy
International Journal of Urology : Official Journal of the Japanese Urological Association|May 21, 2009
Stage I seminoma: what should a practicing uro-oncologist do in 2009?Julia Skliarenko, Danny Vesprini, Padraig Warde
International Journal of Radiation Oncology, Biology, Physics|February 5, 2013
In reply to NiederRobert G Bristow, Charles Catton, Danny Vesprini
Practical Radiation Oncology|July 30, 2022
Minimizing the Risk of Acute Skin Toxicity Due to Hip Prosthesis Avoidance in Prostate Radiation TherapyDavid Y Mak, Danny Vesprini, Melanie Davidson
Cancers|September 9, 2022
The Effect of Age on Prostate Cancer SurvivalRoderick Clark, Danny Vesprini, Steven A Narod
Translational Andrology and Urology|May 26, 2017
Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancerAlireza Fotouhi Ghiam, Danny Vesprini, Stanley K Liu
Prostate Cancer and Prostatic Diseases|January 17, 2025
Prognostic value of MR visibility/invisibility in men on Active SurveillanceLaurence Klotz, Andrew Loblaw, Liying Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2024
Screening guidelines for individuals at increased risk for prostate cancerJustin Lorentz, Julia Woollcombe, Andrew Loblaw, et al.
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Cancer|April 16, 2013
Reply to Monitoring of seminoma patients with serum markersDanny Vesprini, Padraig Warde, Peter Chung
Current Opinion in Urology|March 2, 2013
Predicting high risk disease using serum and DNA biomarkersDanny Vesprini, Stanley Liu, Robert Nam
International Journal of Radiation Oncology, Biology, Physics|September 22, 2023
Elective Nodal Irradiation: Old Game, New SPORTDanny Vesprini, Angela Pathmanathan, Vedang Murthy
International Journal of Urology : Official Journal of the Japanese Urological Association|May 21, 2009
Stage I seminoma: what should a practicing uro-oncologist do in 2009?Julia Skliarenko, Danny Vesprini, Padraig Warde
International Journal of Radiation Oncology, Biology, Physics|February 5, 2013
In reply to NiederRobert G Bristow, Charles Catton, Danny Vesprini
Practical Radiation Oncology|July 30, 2022
Minimizing the Risk of Acute Skin Toxicity Due to Hip Prosthesis Avoidance in Prostate Radiation TherapyDavid Y Mak, Danny Vesprini, Melanie Davidson
Cancers|September 9, 2022
The Effect of Age on Prostate Cancer SurvivalRoderick Clark, Danny Vesprini, Steven A Narod
Translational Andrology and Urology|May 26, 2017
Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancerAlireza Fotouhi Ghiam, Danny Vesprini, Stanley K Liu
Prostate Cancer and Prostatic Diseases|January 17, 2025
Prognostic value of MR visibility/invisibility in men on Active SurveillanceLaurence Klotz, Andrew Loblaw, Liying Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2024
Screening guidelines for individuals at increased risk for prostate cancerJustin Lorentz, Julia Woollcombe, Andrew Loblaw, et al.
Pageof 15